XELOX versus FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer

Publisher Website
Google Scholar
Abstract
The efficacy and tolerability of oxaliplatin in combination with either folinic acid, fluoro-uracil (5-FU) (FOLFOX4 regimen) or capecitabine (XE-LOX regimen) was evaluated in advanced pancreatic cancer.